News
DXR
--
0.00%
--
DAXOR ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH L1 ENTERPRISES GOVERNMENT DISTRIBUTOR
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations), announces today that it has signed a new dist...
GlobeNewswire · 01/13 13:30
DAXOR ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH L1 ENTERPRISES GOVERNMENT DISTRIBUTOR
GlobeNewswire · 01/13 13:30
Daxor to Present at the Inaugural H.C. Wainwright BioConnect 2021 Conference
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations), today announces that Michael Feldschuh, Daxor...
GlobeNewswire · 01/08 13:30
Daxor to Present at the Inaugural H.C. Wainwright BioConnect 2021 Conference
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations), t...
GlobeNewswire · 01/08 13:30
Daxor Corporation Announces Further Acquisitions Of Its BVA-100 Blood Volume Analyzer By Leading Medical Centers Throughout U.S.
Daxor Corporation Announces Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
Benzinga · 12/10/2020 13:33
Daxor Corporation Announces Further Acquisitions of its BVA-100(R) Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces additional acquisitions of Daxor's BVA-100 Blood Volume Analyzer at major med...
GlobeNewswire · 12/10/2020 13:30
Daxor Corporation Announces Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
GlobeNewswire · 12/10/2020 13:30
Daxor Corporation to Present at the 13th Annual LD Micro Main Event 2020
Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor's President and Chief Executive Officer, will p...
GlobeNewswire · 12/09/2020 13:30
Daxor Corporation to Present at the 13th Annual LD Micro Main Event 2020
NEW YORK, NY, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor...
GlobeNewswire · 12/09/2020 13:30
THIRD HOSPITAL JOINS MULTICENTER COVID-19 BVA-100(R) BLOOD TEST STUDY
Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Wake Forest Baptist Health will participate in an ongoing trial to treat...
GlobeNewswire · 11/19/2020 13:30
THIRD HOSPITAL JOINS MULTICENTER COVID-19 BVA-100(R) BLOOD TEST STUDY
Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Wake Forest Baptist Health will participate in an ongoing trial to treat patients hospitalized with COVID-19 utilizing Daxor's BVA-100 (Blood Volume Analyzer, "BVA") technology. Wake Forest School of Medicine is based in Winston-Salem, North Carolina, and is set to enroll patients under the leadership of Ashish K. Khanna, MD.
GlobeNewswire · 11/19/2020 13:30
THIRD HOSPITAL JOINS MULTICENTER COVID-19 BVA-100® BLOOD TEST STUDY
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Wake Forest Baptist Health w...
GlobeNewswire · 11/19/2020 13:30
THIRD HOSPITAL JOINS MULTICENTER COVID-19 BVA-100® BLOOD TEST STUDY
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Wake Forest Baptist Health will participate in an ongoing trial to treat patients hospitalized with COVID-19 utilizing Daxor's BVA-100 (Blood Volume Analyzer, "BVA") technology. Wake Forest School of Medicine is based in Winston-Salem, North Carolina, and is set to enroll patients under the leadership of Ashish K. Khanna, MD. “Having such a prestigious academic and research center such as Wake Forest join the ongoing multi-center trial alongside Oregon Health & Science University and NYU Langone Health highlights the importance of BVA technology in helping clinicians understand COVID-based volume derangements to improve care and outcomes,” said Michael Feldschuh, CEO and President of Daxor. “SARS-CoV-2 attacks the endothelium causing volume derangement and capillary distress. Daxor’s BVA test is the first and only diagnostic test cleared by FDA that offers insights into patients’ capillary leak rate via its albumin tracer in addition to 98% accurate measure of plasma and red cell volume. Elevated leak rate has been shown as a prognostic marker associated with higher mortality, knowledge of it and volume status can be used to triage patients, guide treatment, and measure response to interventions.”“We hope this important trial will help inform volume status and provide crucial insights into COVID-19 pathophysiology,” said Dr. Khanna, Associate Professor in Anesthesiology, Section Head for Research, Section in Critical Care Medicine, Wake Forest School of Medicine.Daxor is the global leader in blood volume measurement technology, utilized by major hospitals in the United States. In a randomized control trial (RCT) published in the journal Shock, the BVA-100® has shown to reduce ICU mortality by 66% (P=0.03) and reduce ventilator days in patients suffering predominantly from acute respiratory distress syndrome and septic shock. Additionally, the analysis showed 44% of BVA test results led to a change in treatment strategy (P=0.004) that care teams would not have performed absent the data from the BVA volume status measure.About Daxor CorporationDaxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.Forward-Looking StatementsCertain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Investor Relations Contact: Bret Shapiro Sr. Managing Partner, CORE IR 516-222-2560 brets@coreir.com
GlobeNewswire · 11/19/2020 13:30
OREGON HEALTH & SCIENCE UNIVERSITY JOINS MULTICENTER COVID-19 BVA-100® STUDY
COVID-19 Investigation Continues at OHSU to Study Hospitalized Patients Utilizing Daxor’s Blood Volume Analysis TechnologyNEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Oregon Health & Science University ("OHSU"), the state’s only comprehensive public academic health center, joins NYU Langone Health as the second site to participate in a trial to treat patients hospitalized with COVID-19 utilizing Daxor's BVA-100 (Blood Volume Analyzer, "BVA") technology. OHSU is based in Portland, Oregon, and is set to begin enrolling patients under the leadership of Martin A. Schreiber, M.D."We are thrilled to have OHSU, one of the leading academic and research centers in the United States, join NYU Langone Health in this critical multicenter COVID-19 BVA trial," said Michael Feldschuh, CEO and President of Daxor. “The exact quantification of total blood, red cell and plasma volume and knowledge of capillary status are unique to Daxor's BVA technology and provides clinicians precise volume measurement that is superior to commonly used indirect estimates. We believe our test can have a significant impact on patient triage, outcomes and optimal use of resources.”The BVA is the first and only diagnostic test cleared by the FDA that directly measures capillary permeability via its albumin tracer, a capability that provides crucial insight into COVID-19 pathophysiology. A persistently elevated leak rate is a prognostic marker associated with higher mortality, which can be used to triage patients, guide treatment, and measure response to interventions. This study aims to show the implications of COVID as an endothelial disease utilizing this unique measure."In light of the fact that the SARS-CoV-2 virus attacks the endothelium causing increasing permeability, this technology could help determine volume status in these patients as well as quantifying the 3rd spacing rate," said Dr. Schreiber, Professor of Surgery, Division of Trauma, Critical Care and Acute Care Surgery, OHSU School of Medicine.In a randomized control trial (RCT) published in 2011 in the journal Shock, the BVA-100® has shown to reduce ICU mortality by 66% and reduce ventilator days in patients suffering predominantly from acute respiratory distress syndrome and septic shock. Additionally, the analysis showed 44% of BVA test results led to a change in treatment strategy (P=0.004) that care teams would not have performed absent the data from the BVA volume status measure.About Daxor CorporationDaxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information, please visit our website at Daxor.com.Forward-Looking StatementsCertain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Investor Relations Contact: Bret Shapiro Sr. Managing Partner, CORE IR 516-222-2560 brets@coreir.com
GlobeNewswire · 10/29/2020 13:30
OREGON HEALTH & SCIENCE UNIVERSITY JOINS MULTICENTER COVID-19 BVA-100® STUDY
COVID-19 Investigation Continues at OHSU to Study Hospitalized Patients Utilizing Daxor’s Blood Volume Analysis TechnologyNEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumen...
GlobeNewswire · 10/29/2020 13:30
OREGON HEALTH & SCIENCE UNIVERSITY JOINS MULTICENTER COVID-19 BVA-100(R) STUDY
COVID-19 Investigation Continues at OHSU to Study Hospitalized Patients Utilizing Daxor's Blood Volume Analysis Technology
GlobeNewswire · 10/29/2020 12:32
OREGON HEALTH & SCIENCE UNIVERSITY JOINS MULTICENTER COVID-19 BVA-100(R) STUDY
COVID-19 Investigation Continues at OHSU to Study Hospitalized Patients Utilizing Daxor's Blood Volume Analysis Technology
GlobeNewswire · 10/29/2020 12:32
Daxor to Present at the 2020 MicroCap Rodeo Best Ideas Bowl
NEW YORK, NY, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor’s President and Chief Executive Officer, will present at the virtual 2020 MicroCap Rodeo Best Ideas Bowl on Tuesday, October 13th at 3:00 PM ET. Mr. Feldschuh will provide a company overview and discuss key highlights including new research recently presented at the Heart Failure Society of American Virtual Annual Scientific Meeting 2020 on the cost- effectiveness and improvement in patient life-span using Daxor’s BVA-100® blood test in heart failure. A Q&A session will follow after the webcast.Event Details Webcast: Tuesday, October 13th, 2020 Time: 3:00 PM Eastern Time Link: https://www.webcaster4.com/Webcast/Page/2134/37954To receive additional information, request an invitation or to schedule a one-on-one meeting, please visit https://microcaprodeo.com.About Daxor CorporationDaxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information, please visit our website at Daxor.com.Forward-Looking StatementsCertain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Investor Relations Contact:Bret Shapiro Sr. Managing Partner, CORE IR 516-222-2560 brets@coreir.com
GlobeNewswire · 10/12/2020 13:30
Daxor to Present at the 2020 MicroCap Rodeo Best Ideas Bowl
NEW YORK, NY, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor...
GlobeNewswire · 10/12/2020 13:30
Daxor to Present at the 2020 MicroCap Rodeo Best Ideas Bowl
Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor's President and Chief Executive Officer, will present at the virtual 2020 MicroCap Rodeo Best Ideas Bowl on Tuesday, October 13th at 3:00 PM ET.
GlobeNewswire · 10/12/2020 12:30
Webull provides a variety of real-time DXR stock news. You can receive the latest news about DAXOR CORP through multiple platforms. This information may help you make smarter investment decisions.
About DXR
Daxor Corporation is an investment company with medical instrumentation and biotechnology operations. The Company focuses on the development of the Blood Volume Analyzer (BVA) -100, an instrument that rapidly and accurately measures human blood volume. The Company’s instrument is used in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.The Company also owns the Daxor Oak Ridge Operations (DORO) facility in Oak Ridge, Tennessee. The semi-automated BVA provides blood volume measurements in human body for diagnosis and treatment in a range of medical and surgical conditions.
More